Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
gptkb:etrasimod
|
| gptkbp:CASNumber |
1204669-58-8
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Arena_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C24H19F3N2O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
APD334
|
| gptkbp:indication |
gptkb:Crohn's_disease
ulcerative colitis |
| gptkbp:intendedUse |
treatment of autoimmune diseases
|
| gptkbp:mechanismOfAction |
S1P1 receptor modulator
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:sphingosine-1-phosphate_receptor_1
|
| gptkbp:bfsParent |
gptkb:Etrasimod
|
| gptkbp:bfsLayer |
6
|